Charles River acquires Retrogenix for $48M

By The Science Advisory Board staff writers

April 1, 2021 -- Charles River Laboratories has paid approximately $48 million U.S. to acquire the U.K.-based contract research organization Retrogenix.

The acquisition strengthens Charles River's expertise with the addition of cell microarray technology and off-target screening for preclinical safety assurance in chimeric antigen receptor (CAR) T-cell therapies. Retrogenix's cell microarray technology can identify specific cell surface and secreted protein interactions in human cells, the firm said.

A potential additional payment of up to $7 million for future performance is included in the deal.

Charles River to pay $875M to buy Cognate BioServices
Charles River Laboratories has signed a deal to pay about $875 million in cash to acquire cell and gene manufacturer Cognate BioServices.
Charles River, Cypre collaborate on in vitro services
Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles...
Charles River Laboratories acquires Distributed Bio
Charles River Laboratories has acquired Silicon Valley-based antibody drug discovery firm Distributed Bio for $83 million in cash.
BioVaxys' COVID-19 vaccine may provide longer protection
BioVaxys Technology has released data about its haptenized viral protein vaccine technology used in BVX-0320, its COVID-19 vaccine candidate. The candidate...
Charles River, Deciphex form digital pathology partnership
Charles River Laboratories has entered into a partnership with software firm Deciphex to offer a digital pathology workflow platform.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter